[The effect of temocapril, an angiotensin-converting enzyme inhibitor with preferential biliary excretion, on experimental diabetic nephropathy].
Tempocapril is a novel angiotensin-converting enzyme (ACE) inhibitor which is preferentially eliminated via the biliary tract. To examine whether it has a protective effect in diabetic nephropathy like conventional ACE inhibitors which are eliminated via the kidney, a study was performed in streptozotocin-induced diabetic rats for 8 months. Male Wistar rats were divided into 4 groups (control rats, diabetic rats treated with temocapril at the doses of 5 mg/l or 15 mg/l of drinking water, and untreated diabetic rats). There was no significant difference in the blood glucose levels of the 3 diabetic groups. Administration of temocapril at both doses of 5 mg/l and 15 mg/l significantly reduced the blood pressure as well as the urinary excretion of albumin and N-acetyl-beta-D-glucosaminidase. However, significant suppression of glomerular basement membrane hypertrophy was only induced by treatment with temocapril at the dose of 15 mg/l. Elevated glomerular filtration rate and filtration fraction in diabetic rats were decreased by tempocapril at the dose of 15 mg/l, but not significantly. These results indicate that tempocapril has a protective effect on diabetic nephropathy like conventional ACE inhibitors.
Yanagisawa
Y
Y
2nd Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D001485:Basement Membrane / Q000473:pathology; D001659:Biliary Tract / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000503:physiopathology; D005919:Glomerular Filtration Rate / Q000187:drug effects; D007678:Kidney Glomerulus / Q000473:pathology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D013841:Thiazepines / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D013841:Thiazepines; D013311:Streptozocin; C055603:temocapril hydrochloride